A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii

Journal of Burn Care and Research

Volumn 34, Issue 4, 2013, Pages 403-412

  Ackerman, Bruce H ^a   Haith, Linwood R ^a   Patton, Mary L ^a   Guilday, Robert E ^a   Reigart, Cynthia L ^a   Stair Buchmann, Megan ^a  

^a CROZER CHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; LEVOFLOXACIN; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BLOOD CULTURE; BRONCHOSCOPY; BURN; DRUG TREATMENT FAILURE; FEMALE; HUMAN; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SPUTUM CULTURE; SURVIVAL; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AMINOGLYCOSIDES; AMPICILLIN; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BURNS; CEPHALOSPORINS; CILASTATIN; COLISTIN; CREATININE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FEVER; FLUOROQUINOLONES; HUMANS; IMIPENEM; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES; SULBACTAM;

EID: 84881164801     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e318270003a     Document Type: Article

References (36)

1. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug- resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004;48: 1586-92. (Pubitemid 38544363)
2. Koprnová J, Svetlanský I, Babel'a R, et al. Prospective study of antibacterial susceptibility, risk factors and outcome of 157 episodes of Acinetobacter baumannii bacteremia in 1999 in Slovakia. Scand J Infect Dis 2001;33: 891-5. (Pubitemid 34083319)
3. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003;31: 2478-82. (Pubitemid 37281732)
4. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006;129: 102-9.
5. Montero A, Corbella X, Ariza J. Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Crit Care Med 2003;31: 2557-9. (Pubitemid 37281747)
6. Theaker C, Azadian B, Soni N. The impact of Acinetobacter baumannii in the intensive care unit. Anaesthesia 2003;58: 271-4. (Pubitemid 36329274)
7. Reis AO, Luz DA, Tognim MC, Sader HS, Gales AC. Polymyxin- resistant Acinetobacter spp. isolates: what is next? Emerging Infect Dis 2003;9: 1025-7.
8. Pandey A, Kapil A, Sood S, Goel V, Das B, Seth P. In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumannii. J Clin Microbiol 1998;36: 3415-16. (Pubitemid 28476210)
9. Visalli MA, Jacobs MR, Moore TD, Renzi FA, Appelbaum PC. Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods. Antimicrob Agents Chemother 1997;41: 767-70. (Pubitemid 27150528)
10. Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clin Microbiol Infect 2005;11: 24-30. (Pubitemid 40227818)
11. Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001;21: 142-8. (Pubitemid 32120147)
12. Goldberg J, Owens RC Jr. Optimizing antimicrobial dosing in the critically ill patient. Curr Opin Crit Care 2002;8: 435-40.
13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26: 1-10; quiz 11-12.
14. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003;17: 579-98. (Pubitemid 38029154)
15. Boucher BA, Kuhl DA, Hickerson WL. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 1992;14: 458-63.
16. Jones ME, Thornsberry C, Livermore DM, Sahm DF. Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network. J Antimicrob Chemother 1999;43: 429-31. (Pubitemid 29121891)
17. Clark RB. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein. J Antimicrob Chemother 1996;38: 245-51. (Pubitemid 26302585)
18. Chastre J. Infections due to Acinetobacter baumannii in the ICU. Semin Respir Crit Care Med 2003;24: 69-78.
19. Thomaskutty M, Ackerman BH, Haith LR Jr, Patton ML, Guilday RL. High-dose ampicillin-sulbactam in the treatment of nosocomial pneumonia of Multi-resistant Acinetobacter Sp in a Burns Unit. Presented at the 24th Annual Eastern States Conference for Pharmacy Residents and Preceptors, Baltimore, MD, May 5-7, 2005.
20. Ackerman BH, Thomaskutty M, Haith LR Jr, Patton ML, Guilday RE. Quality assurance of high dose ampicillin-sulbactam vs imipenem cilastatin in the treatment of nosocomial pneumonia in inhalation injury patients with multi-resistant Acinetobacter baumannii in 102 infected patients receiving 173 treatment courses. Presented at the 29th Annual Mid-Atlantic Burn Conference, Princeton, NJ, November 6-7, 2005.
21. Trottier V, Namias N, Pust DG, et al. Outcome of Acinetobacter baumannii infection in critically ill surgical patients [abstract]. Surgical Infectious Disease Conference A-35.
22. Panchon-Ibanez ME, Jemenez-Mejas ME, Pichardo C, Llanos AC, Panchon J. Activity of Tigecycline (GAR- 936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Ag Chemother 2004;48: 4479-81. (Pubitemid 39434923)
23. Soo Hoo GW, Wen YE, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospitalacquired pneumonia. Chest 2005;128: 2778-87. (Pubitemid 41507640)
24. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128: 3854-62. (Pubitemid 43062645)
25. Ackerman BH, Reigart CL, Stair-Buchmann M, Haith LR Jr, Patton ML, Guilday RE. Use of nebulized antimicrobial agents in burned and mechanically ventilated patients with persistent Acinetobacter baumannii, Pseudomonas aeruginosa, or Enterobacteriacea. Burns 2012; Nov 26. [Epub ahead of print] doi: 10.1016/j.burns.2012.10.026.
26. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between betalactamase production, outer membrane protein and penicillin- binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003;51: 565-74. (Pubitemid 36336148)
27. Das I, Lambert P, Hill D, Noy M, Bion J, Elliott T. Carbapenem- resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect 2002;50: 110-14. (Pubitemid 37554888)
28. Koeleman JG, Stoof J, Van Der Bijl MW, Vandenbroucke- Grauls CM, Savelkoul PH. Identification of epidemic strains of Acinetobacter baumannii by integrase gene PCR. J Clin Microbiol 2001;39: 8-13. (Pubitemid 32059560)
29. Segal H, Elisha BG. Use of Etest MBL strips for the detection of carbapenemases in Acinetobacter baumannii. J Antimicrob Chemother 2005;56: 598. (Pubitemid 41264144)
30. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital- acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171: 388-416.
31. Zaske DE, Chin T, Kohls PR, Solem LD, Strate RG. Initial dosage regimens of gentamicin in patients with burns. J Burn Care Rehabil 1991;12: 46-50.
32. Zaske DE, Cipolle RJ, Rotschafer JC, Solem LD, Mosier NR, Strate RG. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982;21: 407-11. (Pubitemid 12117784)
33. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999;44: 319-27. (Pubitemid 29425682)
34. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005;31: 649-55. (Pubitemid 40684982)
35. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31: 101-6. (Pubitemid 32268946)
36. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005;52: 203-8. (Pubitemid 41133546)